Sign In
Buy DCTH
$10.33
-0.200 (-1.90%)
At Close: Jun 03, 2026
Delcath Systems, Inc. (DCTH) Q2 2025 Earnings Call Transcript
03:06pm, Wednesday, 06'th Aug 2025
Delcath Systems, Inc. (NASDAQ:DCTH ) Q2 2025 Earnings Conference Call August 6, 2025 8:30 AM ET Company Participants David Hoffman - General Counsel, Corporate Secretary & Chief Compliance Officer Ger
Delcath (DCTH) Q2 Revenue Jumps 210%
01:35pm, Wednesday, 06'th Aug 2025
Delcath (DCTH) Q2 Revenue Jumps 210%
Delcath Systems, Inc. (DCTH) Surpasses Q2 Earnings and Revenue Estimates
10:16am, Wednesday, 06'th Aug 2025
Delcath Systems, Inc. (DCTH) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to a loss of $0.48 per share a year ago.
Delcath Systems Reports Second Quarter 2025 Results and Business Highlights
08:00am, Wednesday, 06'th Aug 2025
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic live
Delcath Systems to Participate at the Canaccord Genuity 45th Annual Growth Conference
04:01pm, Tuesday, 29'th Jul 2025
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced tha
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Friday, 25'th Jul 2025
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic canc
Delcath Systems to Host Second Quarter 2025 Earnings Call
04:01pm, Wednesday, 23'rd Jul 2025
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it
Is the Options Market Predicting a Spike in Delcath Systems Stock?
09:35am, Thursday, 17'th Jul 2025
Investors need to pay close attention to DCTH stock based on the movements in the options market lately.
Delcath Systems: Growing Fast, But Business Model Is Fragile
08:36am, Thursday, 12'th Jun 2025
Delcath's HEPZATO shows rapid sales growth and high pricing, but its efficacy is only moderately better than alternatives and not curative. The addressable market is small, treatment is complex, and f
Delcath Systems, Inc. (DCTH) Is Up 0.62% in One Week: What You Should Know
01:01pm, Wednesday, 04'th Jun 2025
Does Delcath Systems, Inc. (DCTH) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts Predict a 48.69% Upside in Delcath Systems (DCTH): Here's What You Should Know
10:56am, Wednesday, 28'th May 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 48.7% in Delcath Systems (DCTH). While the effectiveness of this highly sought-after metric is questionable, th
Here's Why Momentum in Delcath Systems (DCTH) Should Keep going
09:51am, Wednesday, 28'th May 2025
Delcath Systems (DCTH) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Delcath Systems Issues Full Year 2025 Guidance
07:00am, Thursday, 22'nd May 2025
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic live
Delcath Systems: Q1 Earnings Show A Growth Spurt And Switch To Execution
08:25am, Sunday, 18'th May 2025
Delcath's commercial execution post-HEPZATO launch has driven impressive revenue growth, positive cash flow, and a shift from speculative to established biotech. Q1 earnings beat expectations with 530
Delcath Systems to Participate at the Craig-Hallum 22nd Annual Investor Conference
04:30pm, Thursday, 15'th May 2025
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced tha
